Bayerische Motoren Werke ADR (BMWYY)
29.20
+0.00 (0.00%)
OP · Last Trade: Aug 22nd, 1:05 AM EDT
Detailed Quote
| Previous Close | 29.20 |
|---|---|
| Open | - |
| Bid | - |
| Ask | - |
| Day's Range | N/A - N/A |
| 52 Week Range | 25.15 - 31.77 |
| Volume | 0 |
| Market Cap | - |
| PE Ratio (TTM) | - |
| EPS (TTM) | - |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | - |
Chart
News & Press Releases
European financial markets are currently experiencing a period of mixed performance, reflecting a complex interplay of economic data, geopolitical shifts, and the recent announcement of a US-EU trade deal framework. While the pan-European STOXX 600 index has shown slight gains, and the UK's FTSE 100 has seen increases, major national
Via MarketMinute · August 21, 2025
In a significant move poised to reshape global trade dynamics, the United States and the European Union have unveiled a new "Framework on an Agreement on Reciprocal, Fair, and Balanced Trade." Announced on August 21, 2025, this foundational agreement aims to invigorate one of the world's largest trade and investment
Via MarketMinute · August 21, 2025
Clene Inc. (NASDAQ: CLNN) Reports Q2 2025 Results as Company Prepares for NDA Submission and Extends Runway into 2026
Clene (NASDAQ: CLNN) and its wholly owned subsidiary, Clene Nanomedicine Inc., a late clinical-stage biopharmaceutical company focused on improving mitochondrial health and protecting neuronal function to treat neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), released its second quarter 2025 financial results and provided an update on its clinical programs. The company emphasized progress toward an NDA submission for its lead asset CNM-Au8 in ALS, expected in the fourth quarter of 2025 ( https://ibn.fm/PiKqu ).
Via Investor Brand Network · August 21, 2025
Scientists Turn Bacteria into Trojan Horses to Deliver Anti-Cancer Viruses into Tumors
Scientists at Columbia University have engineered a cancer treatment that leverages bacteria to smuggle cancer-killing viruses into tumors in a method that sidesteps the defenses of the immune system. This groundbreaking approach utilizes two vital weapons against the cancer; the bacteria are drawn to cancer cells, and the viruses inside the bacteria deliver the killer blow to the tumor cells after being delivered there by the bacteria.
Via Investor Brand Network · August 21, 2025
If you drive a BMW, you already know — the right parts make all the difference. Whether it’s a complete engine, a pair of BMW headlights, or a small but crucial sensor, the quality and authenticity of that part determine how your car feels, drives, and lasts.
Via AB Newswire · August 20, 2025
BioMedNewsBreaks — BioAdaptives, Inc. (OTCMKTS: BDPT) Receives WADA-Compliant Certification for MyndMed(TM) From TruShield(TM)
BioAdaptives (OTCMKTS: BDPT), a developer of natural health and performance supplements, said its nootropic formula MyndMed(TM) was certified clean by TruShield(TM) Laboratory Services following testing for World Anti-Doping Agency compliance. TruShield, whose protocols are trusted by professional sports organizations including the UFC(R), confirmed MyndMed contains no banned substances and meets safety standards for competitive athletes. BioAdaptives said the clearance supports integration of MyndMed into the UFC’s approved supplement pool, providing fighters with cognitive performance, focus and reaction-time support without risk of anti-doping violations.
Via Investor Brand Network · August 20, 2025
Nutriband Inc. (NASDAQ: NTRB): When Regulatory Momentum Meets Leadership Continuity
The pharmaceutical development landscape presents a fundamental shift as regulatory frameworks evolve beyond traditional efficacy-first approaches. The most significant patient impact now comes from innovations that enhance safety profiles of existing therapeutic options, particularly in pain management where the balance between therapeutic benefit and abuse potential creates urgent medical need alongside substantial regulatory complexity.
Via Investor Brand Network · August 20, 2025
Young Americans Face Health Insurance Chaos as They Turn 26
As young Americans turn 26, they are faced with a major transition that requires them to find their own health insurance since they no longer qualify to remain on the health insurance plan of their family. As many have found out at this transition point, getting your own insurance is a maze with many twists and turns that can leave one baffled and helpless.
Via Investor Brand Network · August 19, 2025
Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF): How a $500K Device Could Reshape the $8.7 Billion Breast Imaging Market
Every year, outdated imaging technologies underperform for the roughly half of women undergoing breast cancer screening who have dense breast tissue. Dense breast tissue creates a fundamental imaging challenge in compression-based imaging, like mammography, where overlapping structures can mask cancers, potentially delaying diagnosis when cancers are small and in their most treatable stages. This limitation represents an $8 billion annual burden in follow-up procedures, repeat imaging, and unnecessary interventions driven by inconclusive results from current screening technologies.
Via Investor Brand Network · August 19, 2025
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) to Present at Emerging Growth Conference on August 20
Nutriband (NASDAQ: NTRB) announced it will participate in the Emerging Growth Conference on August 20, 2025. Chairman Serguei Melnik will deliver a live, interactive presentation and may open the floor for real-time questions from shareholders and the investment community.
Via Investor Brand Network · August 18, 2025
2025 has largely been a year to forget for Tesla investors, but here's some good news for the future.
Via The Motley Fool · August 16, 2025
AI ECU Tuning Backfires: ChatGPT-Generated Car Tunes Are Bricking Engines, Warns Top Tuning Firm Alpine MSS
As the internet floods with “ChatGPT car tuning” tutorials and AI tuning forums praise their so-called revolutionary ECU maps, Alpine MSS is sounding the alarm: amateur tuners using AI-generated calibrations are destroying engines at unprecedented rates.
Via AB Newswire · August 15, 2025
Study Finds That Low BSA Psoriasis Could Have a High Disease Burden
For decades, the severity of psoriasis has been classified on the basis of thresholds reflecting the BSA, or body surface area, impacted by the condition. Under this classification, individuals with less than 3 percent of BSA were categorized as having mild psoriasis; those with a BSA ranging between 3 and 10 percent were regarded as having moderate psoriasis; while those with a BSA in excess of 10 percent were classified as having severe psoriasis.
Via Investor Brand Network · August 15, 2025
What Women Need to Know About Benign Brain Tumors
It is easy to shrug off forgetfulness or a headache as stress. However, this isn’t always the case as those symptoms could point to the possibility of a tumor in the brain. For women, this risk is even higher given that women make up 62.9% of people who develop noncancerous brain tumors. It is therefore important to know what to look out for, and which steps to take.
Via Investor Brand Network · August 14, 2025
Nio's newly launched Onvo L90 SUV is expected to put the EV-maker back on the growth track.
Via The Motley Fool · August 13, 2025
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Advances Phase 3 Alzheimer’s Trial, Strengthens IP Portfolio, Reports Q2 2025 Results
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company developing therapies for neurodegenerative diseases, announced second-quarter 2025 results and corporate updates. The pivotal Phase 3 trial in early Alzheimer’s disease (NCT06709014) now includes 76 secured U.S. sites, with 46 actively enrolling, 38 patients dosed, and nearly 200 in screening. Enrollment is progressing on schedule with a 50% screen failure rate as expected. Recent milestones include presenting four scientific posters at AAIC 2025, hiring a director of biostatistics, hosting a trial update webcast, and securing global IP coverage for crystal buntanetap. As of June 30, 2025, cash and equivalents totaled $17.1 million, up from $10.6 million at year-end 2024. Quarterly R&D expenses were $5.2 million versus $5.8 million in the prior-year period, while G&A expenses declined to $1.1 million from $2.0 million. Net loss per share narrowed to $0.32 from $0.44.
Via Investor Brand Network · August 13, 2025
BioMedNewsBreaks — Fifty 1 Labs, Inc. (OTC: FITY) and BioSpark AI Achieve Major Milestone in AI-Driven Drug Repurposing
Fifty 1 Labs (OTC: FITY), through its subsidiary Fifty1 AI Labs and in partnership with BioSpark AI Technologies Inc., has transformed more than 10,000 unstructured case reports into a structured, queryable database of over 2,000 real-world patient treatment-outcome pathways. Built using BioSpark’s patented natural language processing system and Fifty1’s proprietary AI modeling, the dataset provides a high-fidelity foundation for therapeutic discovery in complex conditions such as chronic fatigue, neuroinflammation and post-viral syndromes. The collaboration, which aligns with Fifty1 Labs’ intent to acquire BioSpark, has prioritized off-patent drug candidates with market opportunities ranging from $1 billion to over $160 billion. The next phase will leverage Fifty1’s AI models to run deep analyses aimed at rapidly generating and prioritizing commercially viable repurposing candidates for clinical validation.
Via Investor Brand Network · August 12, 2025
Parkinson’s-Gut Bacteria Link Suggests Surprisingly Simple Treatment Option
For long, researchers have posited that a link between our brain and gut contributes to the onset of Parkinson’s disease. Now a new study suggests that B-vitamin supplements could address some of the medical needs of Parkinson’s disease patients after their research linked specific vitamin deficiencies to the disease .
Via Investor Brand Network · August 12, 2025
Have you ever wondered why different brands of electric vehicles can automatically match the charging power after plugging in the charging pile ? Why do some charging piles charge fast and others slowly? Behind this is actually a set of “invisible language” controlling – that is, the charging protocol. Today, let’s reveal the “rules of dialogue” between charging piles and electric vehicles !
Via AB Newswire · August 11, 2025
The Federal Reserve finds itself in a precarious position, navigating a complex economic landscape heavily influenced by the unpredictable nature of President Trump's tariff policy. As of August 2025, the central bank maintains a cautious "wait-and-see" approach to its benchmark interest rate, holding it steady at a target range of
Via MarketMinute · August 8, 2025
Breakthrough Treatment for Lung Cancer Uses Mitochondria to Supercharge Immune Cells
Researchers in China have discovered a way to supercharge the treatment of lung cancer by transplanting mitochondria into the tumor environment. This transplantation increases the effectiveness of chemotherapy while boosting the immune system’s ability to fight the cancer. The team combined cisplatin (a lung cancer chemo drug) with mitochondrial transplantation.
Via Investor Brand Network · August 8, 2025
BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Secures FDA Type C Meeting for AVERSA(TM) Fentanyl Abuse-Deterrent Patch
Nutriband (NASDAQ: NTRB), a developer of prescription transdermal pharmaceutical products, announced the U.S. Food and Drug Administration has granted a Type C Meeting on Sept. 18, 2025, to review Chemistry, Manufacturing, and Controls plans for its lead product, AVERSA(TM) Fentanyl. Developed in partnership with Kindeva, the patch integrates Nutriband’s abuse-deterrent technology with Kindeva’s FDA-approved fentanyl patch to help prevent abuse, diversion, misuse, and accidental exposure while maintaining access for patients in need. Positioned to be the world’s first abuse-deterrent opioid patch, AVERSA Fentanyl targets peak annual U.S. sales potential of $80 million to $200 million, with future global market expansion planned. The technology is protected by patents in 46 countries.
Via Investor Brand Network · August 8, 2025
Izotropic Corp. (CSE: IZO) (OTCQB: IZOZF): The Cancer Detection Revolution That Could Make Breast Cancer Deaths Preventable
The medical community stands at the threshold of what could become the most significant advancement in cancer detection since the introduction of mammography over half a century ago. While survival rates for many cancers have improved dramatically through better treatments, the fundamental challenge of early detection remains largely unchanged. Current screening technologies, despite decades of refinement, still miss cancers in their earliest, most treatable stages, while simultaneously generating false positives that lead to unnecessary anxiety and interventions.
Via Investor Brand Network · August 8, 2025
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Secures Full Patent Coverage for New Crystalline Form of Buntanetap
Annovis Bio (NYSE: ANVS), a late-stage clinical company advancing treatments for neurodegenerative diseases, announced the successful transfer and expansion of its intellectual property to fully cover both the original and new crystalline forms of buntanetap. The comprehensive patent portfolio, now protected through 2046, includes composition of matter, mechanism of action, and use in multiple indications. The new form offers improved stability with bioequivalence confirmed in animal and human studies, as presented at the 2025 Alzheimer’s Association International Conference.
Via Investor Brand Network · August 7, 2025